Methods for objective assessment of stress, early detection of risk for stress disorders, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs
AssigneesIndiana University Research and Technology Corporation, The United States of America as Represented by the Department of Veterans Affairs Office
InventorAlexander Bogdan Niculescu
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for assessing severity, determining future risk, matching with a drug treatment, and measuring response to treatment, for stress disorders. Also disclosed are new methods for use for drugs and natural compounds repurposed for use in reducing stress severity, as well as for preventing and treating stress disorders. All the above mentioned methods are computer assisted methods analyzing the expression of panels of genes, clinical measures, and drug databases. A universal approach in everybody, as well as a personalized approaches by gender, and by diagnosis, are disclosed.
Claims5
A computer-assisted method for assessing a high stress state in a subject, the method comprising:
- computing a score based on biomarker expression levels of two panels of blood biomarkers, in one or more samples obtained from the subject;
- computing a reference score based on reference biomarker expression levels obtained from a population of low stress state subjects for the two panels of blood biomarkers;
- and
- identifying a difference between the score in the one or more samples obtained from the subject and the reference score, wherein the difference in the score in the one or more samples obtained from the subject and the reference score indicates a risk for a high stress state in the subject;
- wherein a first panel of blood biomarkers comprises DEAD-Box Helicase 6 (DDX6), Beta-2-Microglobulin (B2M), and Reticulon 4 (RTN4) and an increased score in the first panel for the one or more samples obtained from the subject greater as compared to the reference score indicates a risk for a high stress state;
- wherein a second panel of blood biomarkers comprises FK506 Binding Protein 5 (FKBP5), Leukocyte Associated Immunoglobulin Like Receptor 1 (LAIR1), and MAD 1 Mitotic Arrest Deficient Like 1 (MADIL1) and a decreased score in the second panel for the one or more samples obtained from the subject as compared to the reference score indicates a risk for a high stress state;
- wherein upon the first panel, the second panel, or both the first and second panel indicating a risk for a high stress state, administering a treatment to the subject, wherein the treatment reduces the difference between the score in the one or more samples obtained from the subject and the reference score to mitigate the high stress state in the subject, and wherein a change in score upon administering the treatment indicates a response to the treatment;
- and
- wherein the treatment is a therapy selected in a computer-assisted fashion from the group consisting of one or more new compounds selected from the group consisting of:
- cefotiam, proguanil, hydroxyachillin, Prestwick-682, levopropoxyphene, isoflupredone, ozagrel, streptozocin, cyclopenthiazide, metformin, corticosterone, calcium folinate, diphenhydramine, dapsone, spiramycin, asiaticoside, ambroxol, xamoterol, betulin, isometheptene, primidone, tocainide, diloxanide, alprostadil, doxepin, diltiazem, estriol, molindone, and combinations thereof, each therapy selection based on one or more individual biomarkers of the first panel of blood biomarkers or the second panel of blood biomarkers.
Dependencies are inferred from the claim text.